This company has been marked as potentially delisted and may not be actively trading. NASDAQ:EIGR Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR) 30 days 90 days 365 days Advanced Chart Get EIGR alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.30▼$7.1752-Week Range N/AVolume137,800 shsAverage Volume103,866 shsMarket Capitalization$2.55 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California. Read More Receive EIGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address EIGR Stock News HeadlinesNew Route On Eiger's North Face Will Have to WaitApril 16, 2025 | msn.comRemembering John Harlin, Eiger LegendMarch 23, 2025 | msn.comHave you heard of “E.I.”?Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing to invest in new "E.I." Tech, which one expert estimates will grow by 200,000%. Becoming bigger than the automobile, PC, and cell phone markets... COMBINED!July 4 at 2:00 AM | Behind the Markets (Ad)Eiger BioPharmaceuticals Inc (OTC:EIGRQ) Stock Quotes, Forecast and News SummaryOctober 6, 2024 | benzinga.comEiger Biopharmaceuticals Inc (EIGRQ)September 29, 2024 | investing.comMassive Rockfall on the North Face of the EigerSeptember 8, 2024 | yahoo.comEiger BioPharmaceuticals, Inc. (EIGRQ)August 13, 2024 | finance.yahoo.com72C.SG,0P00015QPW,0 (72C.SG)August 3, 2024 | ca.finance.yahoo.comSee More Headlines EIGR Stock Analysis - Frequently Asked Questions How were Eiger BioPharmaceuticals' earnings last quarter? Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) issued its quarterly earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) earnings per share for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company earned $3.04 million during the quarter, compared to analyst estimates of $2.54 million. Eiger BioPharmaceuticals had a negative net margin of 590.80% and a negative trailing twelve-month return on equity of 332.49%. When did Eiger BioPharmaceuticals' stock split? Shares of Eiger BioPharmaceuticals reverse split on Monday, January 8th 2024.The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Eiger BioPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eiger BioPharmaceuticals investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), COMPASS Pathways (CMPS), Toast (TOST), Globant (GLOB) and Saia (SAIA). Company Calendar Last Earnings11/04/2021Today7/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EIGR CIK1305253 Webwww.eigerbio.com Phone(650) 272-6138Fax650-618-1621Employees56Year FoundedN/AProfitability EPS (Trailing Twelve Months)($59.1592) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$96.78 million Net Margins-590.80% Pretax Margin-590.79% Return on Equity-332.49% Return on Assets-99.77% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.24 Sales & Book Value Annual Sales$15.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$37.68 per share Price / BookN/AMiscellaneous Outstanding Shares1,480,000Free Float1,419,000Market Cap$2.55 million OptionableOptionable Beta1.83 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:EIGR) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTop Picks for Trump’s Pro-Crypto AmericaMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eiger BioPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eiger BioPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.